Skip to main content

Main menu

  • Home
  • Content
    • Current
    • Ahead of print
    • Past Issues
    • JNM Supplement
    • SNMMI Annual Meeting Abstracts
    • Continuing Education
    • JNM Podcasts
  • Subscriptions
    • Subscribers
    • Institutional and Non-member
    • Rates
    • Journal Claims
    • Corporate & Special Sales
  • Authors
    • Submit to JNM
    • Information for Authors
    • Assignment of Copyright
    • AQARA requirements
  • Info
    • Reviewers
    • Permissions
    • Advertisers
  • About
    • About Us
    • Editorial Board
    • Contact Information
  • More
    • Alerts
    • Feedback
    • Help
    • SNMMI Journals
  • SNMMI
    • JNM
    • JNMT
    • SNMMI Journals
    • SNMMI

User menu

  • Subscribe
  • My alerts
  • Log in
  • My Cart

Search

  • Advanced search
Journal of Nuclear Medicine
  • SNMMI
    • JNM
    • JNMT
    • SNMMI Journals
    • SNMMI
  • Subscribe
  • My alerts
  • Log in
  • My Cart
Journal of Nuclear Medicine

Advanced Search

  • Home
  • Content
    • Current
    • Ahead of print
    • Past Issues
    • JNM Supplement
    • SNMMI Annual Meeting Abstracts
    • Continuing Education
    • JNM Podcasts
  • Subscriptions
    • Subscribers
    • Institutional and Non-member
    • Rates
    • Journal Claims
    • Corporate & Special Sales
  • Authors
    • Submit to JNM
    • Information for Authors
    • Assignment of Copyright
    • AQARA requirements
  • Info
    • Reviewers
    • Permissions
    • Advertisers
  • About
    • About Us
    • Editorial Board
    • Contact Information
  • More
    • Alerts
    • Feedback
    • Help
    • SNMMI Journals
  • View or Listen to JNM Podcast
  • Visit JNM on Facebook
  • Join JNM on LinkedIn
  • Follow JNM on Twitter
  • Subscribe to our RSS feeds
OtherBrief Communication

Preliminary clinical experience of cholecystokinin-2 receptor PET/CT imaging using the 68Ga-labeled minigastrin analog DOTA-MGS5 in patients with medullary thyroid cancer

Elisabeth von Guggenberg, Christian Uprimny, Maximilian Klingler, Boris Warwitz, Anna Sviridenko, Steffen Bayerschmidt, Gianpaolo Di Santo and Irene J. Virgolini
Journal of Nuclear Medicine January 2023, jnumed.122.264977; DOI: https://doi.org/10.2967/jnumed.122.264977
Elisabeth von Guggenberg
Department of Nuclear Medicine, Medical University of Innsbruck, Innsbruck, Austria, Austria
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Christian Uprimny
Department of Nuclear Medicine, Medical University of Innsbruck, Innsbruck, Austria, Austria
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Maximilian Klingler
Department of Nuclear Medicine, Medical University of Innsbruck, Innsbruck, Austria, Austria
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Boris Warwitz
Department of Nuclear Medicine, Medical University of Innsbruck, Innsbruck, Austria, Austria
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Anna Sviridenko
Department of Nuclear Medicine, Medical University of Innsbruck, Innsbruck, Austria, Austria
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Steffen Bayerschmidt
Department of Nuclear Medicine, Medical University of Innsbruck, Innsbruck, Austria, Austria
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Gianpaolo Di Santo
Department of Nuclear Medicine, Medical University of Innsbruck, Innsbruck, Austria, Austria
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Irene J. Virgolini
Department of Nuclear Medicine, Medical University of Innsbruck, Innsbruck, Austria, Austria
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Figures & Data
  • Supplemental
  • Info & Metrics
  • PDF
Loading

Article Figures & Data

Additional Files

  • Supplemental Data

    Files in this Data Supplement:

    • Supplemental Data
PreviousNext
Back to top

In this issue

Journal of Nuclear Medicine: 66 (5)
Journal of Nuclear Medicine
Vol. 66, Issue 5
May 1, 2025
  • Table of Contents
  • Table of Contents (PDF)
  • About the Cover
  • Index by author
  • Complete Issue (PDF)
Download PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for your interest in spreading the word on Journal of Nuclear Medicine.

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
Preliminary clinical experience of cholecystokinin-2 receptor PET/CT imaging using the 68Ga-labeled minigastrin analog DOTA-MGS5 in patients with medullary thyroid cancer
(Your Name) has sent you a message from Journal of Nuclear Medicine
(Your Name) thought you would like to see the Journal of Nuclear Medicine web site.
Citation Tools
Preliminary clinical experience of cholecystokinin-2 receptor PET/CT imaging using the 68Ga-labeled minigastrin analog DOTA-MGS5 in patients with medullary thyroid cancer
Elisabeth von Guggenberg, Christian Uprimny, Maximilian Klingler, Boris Warwitz, Anna Sviridenko, Steffen Bayerschmidt, Gianpaolo Di Santo, Irene J. Virgolini
Journal of Nuclear Medicine Jan 2023, jnumed.122.264977; DOI: 10.2967/jnumed.122.264977

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Share
Preliminary clinical experience of cholecystokinin-2 receptor PET/CT imaging using the 68Ga-labeled minigastrin analog DOTA-MGS5 in patients with medullary thyroid cancer
Elisabeth von Guggenberg, Christian Uprimny, Maximilian Klingler, Boris Warwitz, Anna Sviridenko, Steffen Bayerschmidt, Gianpaolo Di Santo, Irene J. Virgolini
Journal of Nuclear Medicine Jan 2023, jnumed.122.264977; DOI: 10.2967/jnumed.122.264977
Twitter logo Facebook logo LinkedIn logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One
Bookmark this article

Jump to section

  • Article
  • Figures & Data
  • Supplemental
  • Info & Metrics
  • PDF

Related Articles

  • PubMed
  • Google Scholar

Cited By...

  • Safety, Biodistribution, and Radiation Dosimetry of the 68Ga-Labeled Minigastrin Analog DOTA-MGS5 in Patients with Advanced Medullary Thyroid Cancer and Other Neuroendocrine Tumors
  • Preclinical Evaluation of Minigastrin Analogs and Proof-of-Concept [68Ga]Ga-DOTA-CCK-66 PET/CT in 2 Patients with Medullary Thyroid Cancer
  • Google Scholar

Similar Articles

Keywords

  • Oncology: Endocrine
  • Peptides
  • PET/CT
  • cholecystokin-2 receptor
  • gallium-68
  • medullary thyroid cancer
  • minigastrin
  • Positron Emission Tomography
SNMMI

© 2025 SNMMI

Powered by HighWire